Therefore, MET-positive CTCs could be a potential predictive marker in deciding therapeutic strategies [36,42], also considering that therapies directed against MET have shown remarkable responses, specifically in NSCLC patients [43,44,45,46]. This evidence concerns the gene MET and non-small cell lung carcinoma.